Artelo Biosciences (NASDAQ:ARTL) Releases Earnings Results, Misses Estimates By $0.43 EPS

Artelo Biosciences (NASDAQ:ARTL) announced its quarterly earnings data on Monday. The company reported ($1.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.43), Zacks reports.

Artelo Biosciences Price Performance

Shares of Artelo Biosciences stock opened at $1.04 on Wednesday. The business’s 50 day simple moving average is $1.17 and its two-hundred day simple moving average is $1.16. The stock has a market capitalization of $3.34 million, a P/E ratio of -0.36 and a beta of 1.25. Artelo Biosciences has a one year low of $0.91 and a one year high of $1.70.

Wall Street Analyst Weigh In

ARTL has been the topic of a number of research reports. D. Boral Capital reissued a “buy” rating and set a $6.00 price objective on shares of Artelo Biosciences in a report on Thursday, February 27th. HC Wainwright reissued a “buy” rating and set a $5.00 price objective on shares of Artelo Biosciences in a report on Tuesday. Finally, LADENBURG THALM/SH SH raised Artelo Biosciences to a “strong-buy” rating in a report on Wednesday, December 25th.

About Artelo Biosciences

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.